XENE
Xenon Pharmaceuticals Inc.
$67.71
+0.41 (+0.61%)
At close · Jul 15
Market Cap
$6.47B
Shares
96,665,550
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.5M
FY2025
Net Income
-$345.91M
-47.6%
FY2025
Operating Margin
-4974.27%
FY2025
Diluted EPS
-$4.36
-44.9%
FY2025
Operating Cash Flow
-$279.12M
-53.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $7.5M | $0 | $0 | $9.43M | $18.44M | $32.17M | $6.83M | — | $311K | $1.8M | $15.58M | $28.37M | $27.36M | $14.31M | |
| $328.25M | $300.94M | $210.39M | $167.51M | $105.77M | $75.46M | $50.52M | $38.85M | $23.63M | $25.57M | $19.83M | $15.15M | $11.77M | $12.3M | $10.46M | |
| $84.41M | $79.63M | $68.9M | $46.54M | $32.81M | $21.97M | $12.94M | $10.8M | $8.41M | $7.31M | $6.79M | $9.79M | $5.5M | $5.34M | $7.01M | |
| — | $2.54M | $2.56M | $2.06M | $1.41M | $906K | $644K | $429K | $586K | $649K | $864K | $1.04M | $738K | $705K | $786K | |
| $412.66M | $380.57M | $279.3M | $214.05M | $138.58M | $97.43M | $63.47M | $49.65M | $38.04M | $32.89M | $26.62M | $24.94M | $17.26M | $17.64M | $17.46M | |
| -$412.66M | -$373.07M | -$279.3M | -$214.05M | -$129.14M | -$78.99M | -$31.3M | -$42.82M | -$38.04M | -$32.58M | -$24.82M | -$9.36M | $11.11M | $9.71M | -$3.15M | |
| — | -4974.27% | — | — | -1368.91% | -428.45% | -97.31% | -627.02% | — | -10474.28% | -1376.43% | -60.1% | 39.15% | 35.5% | -22.04% | |
| — | -$370.53M | -$276.74M | -$211.99M | -$127.74M | -$78.09M | -$30.66M | -$42.39M | -$37.45M | -$31.93M | -$23.95M | -$8.32M | $11.84M | $10.42M | -$2.37M | |
| — | — | — | — | — | — | $484K | $1.43M | $1.39M | — | — | — | — | $64K | $93K | |
| $25.65M | $26.83M | $41.94M | $27.62M | $8.71M | $466K | $2.28M | $2.35M | $1.22M | $477K | $504K | $542K | $568K | $338K | $144K | |
| $27.51M | $28.18M | $40.88M | $31.37M | $3.89M | $105K | $2.21M | — | — | — | — | — | — | — | — | |
| -$385.15M | -$344.89M | -$238.42M | -$182.69M | -$125.26M | -$78.89M | -$29.09M | -$41.62M | -$34.52M | — | — | — | — | — | — | |
| -$1.98M | $1.02M | -$4.09M | -$292K | $118K | -$6000 | -$257K | -$23K | -$24K | — | — | — | $0 | $0 | $0 | |
| -$383.17M | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -$78.88M | -$28.84M | -$41.6M | -$34.5M | -$30.7M | -$23M | -$15.75M | $13.02M | $12.03M | -$4.3M | |
| — | -4612.13% | — | — | -1328.95% | -427.85% | -89.65% | -609.09% | — | -9872.67% | -1275.49% | -101.12% | 45.89% | 43.98% | -30.06% | |
| — | — | -$234.33M | -$182.39M | -$124.94M | -$77.09M | -$28.01M | -$40.03M | -$31.62M | -$30.7M | -$23M | -$15.75M | $13.02M | $3.83M | -$4.3M | |
| -$383.54M | -$343.96M | -$235.87M | -$179.47M | -$127.38M | -$78.88M | -$28.84M | — | — | — | -$23M | -$15.75M | $9.52M | $10.8M | -$3.96M | |
| USD/shares | — | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 | — | -$1.63 | -$1.71 | -$1.48 | -$1.10 | $4.11 | $2.87 | -$3.24 |
| USD/shares | — | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 | — | -$1.63 | -$1.72 | -$1.48 | -$1.10 | $3.28 | $1.91 | -$3.24 |
| shares | — | 79.25M | 77.89M | 66.89M | 60.54M | 43.63M | 34.54M | 25.94M | 19.43M | 17.99M | 15.49M | 14.28M | 3.17M | 1.34M | 1.33M |
| shares | — | 79.25M | 77.89M | 66.89M | 60.54M | 43.63M | 34.54M | 25.94M | 19.43M | 18M | 15.49M | 14.28M | 3.96M | 2.01M | 1.33M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.49×
P/E (TTM)
—
Biotechnology median 7.39×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| License And Service | $0 | $0 | $9,434,000 | $18,437,000 | $32,166,000 |
Key facts
CIK
1582313
CUSIP
98420N105
13F (30d)
12 filings
12 filers
Visit website
Investor relations